Literature DB >> 32064620

The role of miR-34 in cancer drug resistance.

Sanaz Naghizadeh1, Ali Mohammadi2, Pascal H G Duijf3,4, Behzad Baradaran1, Elham Safarzadeh5, William Chi-Shing Cho6, Behzad Mansoori1,2,7.   

Abstract

Resistance to conventional chemotherapy remains a major cause of cancer relapse and cancer-related deaths. Therefore, there is an urgent need to overcome resistance barriers. To improve cancer treatment approaches, it is critical to elucidate the basic mechanisms underlying drug resistance. Increasingly, the mechanisms involving micro-RNAs (miRNAs) are studied because miRNAs are also considered practical therapeutic options due to high degrees of specificity, efficacy, and accuracy, as well as their ability to target multiple genes at the same time. Years of research have firmly established miR-34 as a key tumor suppressor miRNA whose target genes are involved in drug resistance mechanisms. Indeed, numerous articles show that low levels of circulating miR-34 or tumor-specific miR-34 expression are associated with poor response to chemotherapy. In addition, elevation of inherently low miR-34 levels in resistant cancer cells effectively restores sensitivity to chemotherapeutic agents. Here, we review this literature, also highlighting some contradictory observations. In addition, we discuss the potential utility of miR-34 expression as a predictive biomarker for chemotherapeutic drug response. Although caution needs to be exercised, miR-34 is emerging as a biomarker that could improve cancer precision medicine.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  RNAi; chemotherapy; drug resistance; miR-34; precision oncology

Year:  2020        PMID: 32064620     DOI: 10.1002/jcp.29640

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

Review 1.  Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.

Authors:  Zhimin Yang; Tang Liu; Xiaolei Ren; Mei Yang; Chao Tu; Zhihong Li
Journal:  Cell Cycle       Date:  2022-06-14       Impact factor: 5.173

Review 2.  Novel Effects of Statins on Cancer via Autophagy.

Authors:  Daniela Mengual; Luz Elena Medrano; Wendy Villamizar-Villamizar; Estefanie Osorio-Llanes; Evelyn Mendoza-Torres; Samir Bolívar
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-24

3.  MiR-34c promotes hepatic stellate cell activation and Liver Fibrogenesis by suppressing ACSL1 expression.

Authors:  Binbin Li; Jiaxuan Liu; Xuan Xin; Lifen Zhang; Jiaming Zhou; Chunyan Xia; Weijian Zhu; Hongyu Yu
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

Review 4.  Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment.

Authors:  Rebecca Raue; Ann-Christin Frank; Shahzad Nawaz Syed; Bernhard Brüne
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

Review 5.  MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies.

Authors:  Mahrou Vahabi; Giovanni Blandino; Silvia Di Agostino
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

6.  MicroRNA-506 has a suppressive effect on the tumorigenesis of nonsmall-cell lung cancer by regulating tubby-like protein 3.

Authors:  Zhan-Hua Li; Ji-Hong Zhou; Si-Ning Chen; Ling Pan; Yuan Feng; Mei-Qun Luo; Rui-Xiang Li; Gui-Li Sun
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.